PERFECTHA® FINE LINES

Where can I buy this product?

PERFECTHA® FINE LINES may be available for purchase through Health Supplies Plus by licensed medical practitioners holding a valid medical license, for use only where legally permissible according to local and national regulations. First-time buyers can register an online account by providing required professional information, including medical license verification and a valid shipping address. Account verification is typically completed within 2 business hours, after which you can purchase medical supplies at competitive wholesale pricing. Registered members may also be eligible for volume discounts and receive dedicated customer service support.

Product Information

What is PERFECTHA® FINE LINES?

PERFECTHA® FINE LINES is a sterile, viscoelastic, injectable gel composed of cross-linked hyaluronic acid (HA) of non-animal origin, manufactured by Sinclair Pharma (France). It utilizes Sinclair’s proprietary E-brid™ technology, stated by the manufacturer to create a structured HA gel with claimed low levels of residual BDDE.

This formulation is designed as the lowest viscosity filler in the Perfectha range, typically containing 20mg/mL of hyaluronic acid. It is specifically intended for injection into the superficial dermis to correct fine, superficial lines and wrinkles. This formulation does not contain lidocaine.

Storage: Store according to manufacturer guidelines, typically between 2°C and 30°C (36°F and 86°F). Do not freeze. Protect from light.

Authenticity: Health Supplies Plus guarantees that PERFECTHA® products sourced are authentic from the manufacturer or authorized distributors.

Note: For professional use only by trained and licensed practitioners in jurisdictions where its use is legally permitted.

How does PERFECTHA® FINE LINES work?

PERFECTHA® FINE LINES is engineered using E-brid™ technology to function as a low-viscosity filler ideal for superficial dermal placement. When injected precisely into fine lines (e.g., crow’s feet, superficial perioral lines), the HA gel physically fills the depressions, smoothing the skin’s surface.

Its formulation is designed for smooth integration within the upper layers of the skin without creating excessive bulk. The manufacturer claims the E-brid™ process contributes to the gel’s properties. The hydrophilic nature of HA also helps maintain local skin hydration.

Treatment results are intended to be visible immediately. The manufacturer suggests a duration of effect lasting approximately 4 to 6 months, reflecting its use for more superficial corrections compared to deeper fillers. As this product is lidocaine-free, appropriate anesthesia (e.g., topical) should be considered for patient comfort.

Indications for Use

PERFECTHA® FINE LINES is typically indicated for adults seeking correction of superficial facial lines:

• Periorbital lines (crow’s feet).
• Superficial perioral lines (fine vertical lip lines).
• Fine forehead lines.
• Other superficial wrinkles requiring precise, fine correction.

It is not intended for deep wrinkles or significant volume restoration. Appropriate patient selection and superficial injection techniques are crucial where its use is permitted.

Primary Benefits

• Specifically designed for correcting fine, superficial lines and wrinkles.
• Low viscosity formulation suitable for delicate areas and superficial placement.
• Utilizes E-brid™ technology (claimed low residual BDDE).
• Provides immediate smoothing results.
• Results claimed to last 4-6 months.
• Lidocaine-free formulation.

Side Effects and Safety Information

Common side effects expected with superficial HA filler injections include temporary, injection-site related reactions:

• Bruising
• Redness
• Swelling (usually mild)
• Tenderness or Pain
• Itching
• Small bumps or slight unevenness (usually resolve quickly)
• Increased Sensitivity

Severe Adverse Events:
While serious complications are less frequent with superficial injections compared to deep fillers, potential risks exist. Practitioners must be prepared to manage adverse events. Potential severe adverse events include:

• Vascular Occlusion (VO): Although the risk is lower with superficial injection, accidental intravascular injection is still possible, particularly in high-risk areas (e.g., glabella, periorbital). Prompt recognition and management are crucial.
• Severe allergic reactions or hypersensitivity to HA
• Inflammation or infection at injection sites
• Persistent nodules or granuloma formation (rare)
• Skin discoloration (Tyndall effect if injected too superficially)
• Herpetic eruptions (cold sores) in susceptible individuals
• Hematomas

Any signs of vascular compromise, infection, hypersensitivity, or persistent adverse reactions require immediate medical evaluation.